Researchers of Mashhad University of Medical Sciences succeeded in preparing and producing an effective drug to improve the pulmonary symptoms of Covid-19 disease under the brand name "Covixir Pars".

Dr. Mehrdad Iranshahi, Professor of Pharmacognosy Department and CEO of Knowledge enterprise Gol Elixir Pars Company located in Mashhad University of Medical Sciences, stated: This drug is produced from the gum of desert Comaii (Ferula foetida), its standardization steps based on active ingredients are accurate. It can be used with the permission of the Food and Drug Administration to help relieve the pulmonary symptoms of Covid 19 patients. The effectiveness of this drug has been proven after one year of clinical study (with the permission of the University Ethics Committee) on more than 500 outpatients and coronary patients.

This researcher of Mashhad University of Medical Sciences stated: Pars coxsavir drug is rich in polysulfide compounds that cause the release of hydrogen sulfide in physiological amounts in the body. In recent years, the role of hydrogen sulfide-releasing drugs in improving the function of the respiratory system and combating viral respiratory diseases has received much attention, and its results have been published in prestigious international journals.Dr. Iranshahi pointed out: According to authoritative international articles, hydrogen sulfide-releasing drugs reduce the level of cytokines and reduce pneumonia. On the other hand, they prevent the virus from multiplying and entering the lung cells. The effect of hydrogen sulfide-releasing drugs on increasing lung glutathione stores has also been proven.